Bringing the fundamentals into focus…
Back to Moderna, Inc.
How Moderna, Inc. stacks up
MRNA · against 42 other Healthcare companies of similar size
Growth
5/ 100
Near the bottom of its peers.
Ranked #43 of 43 · scores higher than 0% of peers
Bars: peers in each 10-point band of the growth score1 peers with a growth score of 0–9, including MRNA · Click a bar to see the companies
Why growth scores 5?
Weighted metrics compared with all Healthcare companies.Mainly because of its 3-year revenue growth, revenue growth and earnings per share growth, which are weaker than most Healthcare peers.
- slower revenue growth over three years: weaker than 98% of peers. 3-year revenue growth: -40.6% vs peer median 5.8%
- slower revenue growth over the last year: weaker than 92% of peers. Revenue growth: -27.6% vs peer median 6.1%
- The loss per share widened. Earnings per share growth: — vs peer median 9.8%
Metric by metric
Position: dot = MRNA, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | MRNA | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Revenue growthHigher is better · 43 reported | -27.6% | 8.6% | 0% | 33% | |
| Earnings per share growthHigher is better · 36 reported | Not reported | 19.1% | — | — | 33% |
| 3-year revenue growthHigher is better · 43 reported | -40.6% | 7.0% | 0% | 33% |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by growth score
Top 5 and the companies ranked around MRNA| Rank | Company | Market cap | Growth | Overall |
|---|---|---|---|---|
| 1 | 56.7B USD | 96 | 79 | |
| 2 | 56.0B USD | 86 | 39 | |
| 3 | 67.60T KRW (≈$48.7B) | 82 | 72 | |
| 4 | 126.5B USD | 78 | 56 | |
| 5 | 534.1B HKD (≈$68.4B) | 76 | 75 | |
| 39 | 54.9B USD | 40 | 59 | |
| 40 | 64.8B EUR (≈$71.3B) | 29 | 51 | |
| 41 | 66.3B USD | 20 | 30 | |
| 42 | 171.0B USD | 14 | 45 | |
| 43 | 91.2B USD | 5 | 18 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score